|
Scientific investigations of the peptide cocktail Sanarin In vitro studies - EC50 Determination for 12-peptide cocktail, Doxorubicin and Cisplatin as Single Agents and a Combination Peptide cocktail against MCF-7 Human Pleural Effusion Breast Adenocarcinoma Cells. PDF - EC50 Determination for Combination 12-peptide cocktail and Doxorubicin and Cisplatin as Single Agents against MCF-7 Human Pleural Effusion Breast Adenocarcinoma Cells. PDF - Time Course of 12-Peptide cocktail Effect on MCF-7 Cell Line Proliferation. PDF - 12-Peptide cocktail (Two Dose) Time Course Effect on MCF-7 Cell Line Proliferation. PDF In vivo studies - Efficacy Evaluation of a Twelve Peptide cocktail Against Established, Estrogen supplemented MCF-7 Human Mammary Carcinoma Xenografts. PDF - Efficacy Evaluation of a Twelve PEG-Peptide cocktail and a Twelve Peptide cocktail Against Established Mammary 25 Murine Mammary Carcinoma. PDF - Efficacy Evaluation of a Twelve Peptide cocktail Against Established M25 Murine Mammary Carcinoma in BALB/c Mice. PDF - Efficacy Evaluation of a Twelve PEG-Peptide cocktail and a twelve Peptide (non-PEG) cocktail Against Established MCF-7 (with Estradiol) Human Breast Carcinoma Xenografts. PDF
|
|
Recent developments |
|
What is Sanare's activity? Are you in a hurry or looking for a brief explanation of Sanare's activity? Read more... |
| November 2009: Full studies from Charles River Laboratories, Ann Arbor. |
| October 2009: International patent survey successful. PCT patenting process to start in 2010. Read more... |
Copyright © 2007-2009 Sanare A.S.
Sanare A.S. Tinghaugveien 435, 3175 Ramnes. Norway. Org. nr.
991489029
Tel: +47 9132 7347 Fax: +47 3339 7855
